Holen Sie sich die Stockscreener-App
10.58
5.70%
-0.64
Schlusskurs vom Vortag:
$11.22
Offen:
$11.31
24-Stunden-Volumen:
281.98K
Relative Volume:
0.77
Marktkapitalisierung:
$572.79M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-2.3611
EPS:
-4.481
Netto-Cashflow:
-
1W Leistung:
-15.63%
1M Leistung:
+26.56%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$10.18
$11.31
1-Wochen-Bereich:
$10.18
$12.94
52-Wochen-Spanne:
$7.90
$16.50
Eikon Therapeutics Inc Stock (EIKN) Company Profile
Firmenname
Eikon Therapeutics Inc
Sektor
Branche
Telefon
341-777-0566
Adresse
230 HARRIET TUBMAN WAY, MILLBRAE
Compare EIKN vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EIKN
Eikon Therapeutics Inc
|
10.58 | 572.79M | 0 | 0 | 0 | -4.481 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Eikon Therapeutics Inc Stock (EIKN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-02 | Eingeleitet | BofA Securities | Buy |
| 2026-03-02 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2026-03-02 | Eingeleitet | JP Morgan | Overweight |
| 2026-03-02 | Eingeleitet | Mizuho | Outperform |
| 2026-03-02 | Eingeleitet | Morgan Stanley | Overweight |
| 2026-02-26 | Eingeleitet | Wedbush | Underperform |
Alle ansehen
Eikon Therapeutics Inc Aktie (EIKN) Neueste Nachrichten
Is Eikon Therapeutics, Inc. (EIKN) Stock a Biotech Growth Opportunity Despite Limited Q1 Updates? - Yahoo Finance
Eikon Therapeutics, Inc.(NasdaqGS: EIKN) added to Russell 2000 Index - marketscreener.com
Eikon Therapeutics, Inc.(NasdaqGS:EIKN) added to Russell Microcap Value Benchmark Index - marketscreener.com
Eikon Therapeutics, Inc.(NasdaqGS: EIKN) added to Russell 2000 Value Benchmark - marketscreener.com
Eikon Therapeutics, Inc.(NasdaqGS:EIKN) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Eikon Therapeutics, Inc.(NasdaqGS: EIKN) added to Russell 2000 Growth Benchmark - marketscreener.com
Eikon Therapeutics, Inc.(NasdaqGS: EIKN) added to Russell 3000E Growth Benchmark - marketscreener.com
Eikon Therapeutics, Inc.(NasdaqGS: EIKN) added to Russell Microcap Index - marketscreener.com
Eikon Therapeutics to join Russell 3000 index - MSN
Eikon Therapeutics to Join the Russell 3000 Index - marketscreener.com
Enterprise value to EBITDA forward of Eikon Therapeutics, Inc. – NASDAQ:EIKN - TradingView
Eikon Therapeutics เตรียมเข้าคำนวณในดัชนี Russell 3000 หลังการปรับโครงสร้างดัชนีประจำปี - Moomoo
Price to sales forward of Eikon Therapeutics, Inc. – NASDAQ:EIKN - TradingView
Eikon Therapeutics, Inc. Actuals & Estimates (NASDAQ:EIKN) - TradingView
Price to book forward of Eikon Therapeutics, Inc. – NASDAQ:EIKN - TradingView
Eikon Therapeutics to join Russell 3000 Index on Friday By Investing.com - Investing.com South Africa
Price to earnings forward of Eikon Therapeutics, Inc. – BOATS:EIKN - TradingView
Enterprise value to EBIT forward of Eikon Therapeutics, Inc. – BOATS:EIKN - TradingView
Price to book forward of Eikon Therapeutics, Inc. – BOATS:EIKN - TradingView
Price to sales forward of Eikon Therapeutics, Inc. – BOATS:EIKN - TradingView
Eikon Therapeutics to join Russell 3000 Index on Friday - Investing.com
Eikon Therapeutics to Join Russell 3000 Index Following Annual Reconstitution - Quiver Quantitative
Eikon Therapeutics to Join the Russell 3000® Index - The Manila Times
EIKN Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to revenue forward of Eikon Therapeutics, Inc. – NASDAQ:EIKN - TradingView
Price to earnings forward of Eikon Therapeutics, Inc. – NASDAQ:EIKN - TradingView
Eikon Therapeutics, Inc.(NasdaqGS: EIKN) added to S&P Global BMI Index - marketscreener.com
Eikon Therapeutics Ord Shs (EIKN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Eikon Therapeutics Ord Shs (EIKN) Institutional Confidence - TradingKey
Eikon Therapeutics (EIKN) Slips 1.23% as Stock Tests Key Support at $9.13Entry Point Alerts - dars.gov.et
IPO Tracker 2026: Cardio biotech Kardigan binds off $400M upsized IPO - BioSpace
Eikon Therapeutics Ord Shs (EIKN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Eikon Therapeutics: Buy TLR Combinatory Potential Only After Lock-Up Expiry - Seeking Alpha
Soros opened a brand new EIKN position — moomoo's New tab ca...moomoo Community - Moomoo
Eikon Therapeutics: Initiating Coverage With A Cautious Buy Rating (NASDAQ:EIKN) - Seeking Alpha
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Eikon Therapeutics Appoints Ma. Fatima Francisco to Board - The Globe and Mail
New director and stock option grant at Eikon Therapeutics (NASDAQ: EIKN) - Stock Titan
EIKN Q1 2026 Earnings: Wider-than-Expected Loss Highlights Pre-Revenue ChallengesLow Estimate Range - dars.gov.et
Eikon Therapeutics (EIKN) Short Interest & Short Float | Updated Jun 2026 - MarketBeat
Eikon Therapeutics discloses new USP1 inhibitors - BioWorld News
Eikon Therapeutics, Inc. Announces Appointment of Ma. Fatima D. Francisco as Independent Director and Compensation Committee Member, Effective June 15, 2026 - marketscreener.com
Eikon Therapeutics appoints Francisco to board of directors By Investing.com - Investing.com Nigeria
Eikon Therapeutics appoints Francisco to board of directors - Investing.com India
Eikon Therapeutics Announces the Appointment of Ma. Fatima D. Francisco to its Board of Directors - The Manila Times
Eikon Therapeutics, Inc. Stock 12‑Month Price Target Cut to $24.8, Implies 158% Upside - TradingView
BofA Securities Maintains Eikon Therapeutics(EIKN.US) With Buy Rating, Cuts Target Price to $32 - Moomoo
Cantor Fitzgerald reiterates Overweight on Eikon stock By Investing.com - Investing.com Australia
Cantor Fitzgerald reiterates Overweight on Eikon stock - Investing.com UK
Finanzdaten der Eikon Therapeutics Inc-Aktie (EIKN)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.64%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):